34 citations
,
September 1997 in “Acta Dermato Venereologica” RXR agonists may promote hair growth in humans.
March 2023 in “Biomedicine & Pharmacotherapy” GPR40 agonists help hair growth through the protein ANGPTL4.
July 2022 in “Research Square (Research Square)” Lower PPARγ levels and specific gene variations are linked to more severe Frontal Fibrosing Alopecia.
May 2024 in “Drug discovery today” Thyroid receptor β can help develop new drugs to treat hair loss.
November 2022 in “Journal of Investigative Dermatology” Activating a bitter taste receptor in hair follicles can stop hair growth by increasing a specific growth factor.
November 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Different types of PPARγ are found in varying amounts in human skin and its parts, which could affect how skin treatments work.
1 citations
,
May 2024 in “International Journal of Molecular Sciences” Adenosine receptors could be promising targets for treating inflammatory skin diseases like psoriasis.
September 2025 in “Cureus” GLP-1 agonists may help treat certain skin conditions.
31 citations
,
October 2010 in “Progress in lipid research” LPA3 is crucial for embryo implantation and links LPA to prostaglandin signaling.
46 citations
,
November 2004 in “Lipids” PPARs help regulate skin health and could be used to treat skin disorders.
37 citations
,
March 2006 in “Regulatory Peptides” Mice skin has components that could help with hair growth and might be used for diabetes treatment.
36 citations
,
July 2022 in “Journal of Medicinal Chemistry” Therapies targeting the androgen receptor are being developed to treat prostate cancer and improve bone and muscle health.
28 citations
,
January 2010 in “Biological & pharmaceutical bulletin” Certain essential oils can activate a human skin receptor, potentially helping with skin disorders.
January 2024 in “OPAL (Open@LaTrobe) (La Trobe University)” TRPV3 channels are involved in skin processes and are affected by shear stress, influencing itch and mechanotransduction.
56 citations
,
November 2010 in “Pigment Cell & Melanoma Research” Brain hormones significantly affect hair color and could potentially be used to prevent or reverse grey hair.
4 citations
,
March 2025 in “Journal of Cosmetic Dermatology” Semaglutide may cause hair loss, but more research is needed to confirm this.
4 citations
,
January 2019 in “Therapeutic Advances in Endocrinology and Metabolism” Medications for PCOS don't seem to raise heart disease risk.
3 citations
,
September 2025 in “Frontiers in Cardiovascular Medicine” Women with PCOS have a higher risk of heart disease.
2 citations
,
December 2022 in “Journal of Clinical Medicine” Medications for glucose metabolism and weight control, combined therapy options, and herbal medicines may help regulate menstrual cycle in adolescents with PCOS.
1 citations
,
October 2025 in “Journal of Personalized Medicine” Weight loss improves PCOS symptoms and overall health.
1 citations
,
August 2025 GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.
January 2026 in “Quality in Sport” Semaglutide may help some skin disorders but can also cause skin issues.
December 2024 in “Cureus” Tirzepatide improved symptoms and hair regrowth in a man with folliculitis decalvans.
July 2023 in “Journal of Clinical Medicine” Tirzepatide might help manage PCOS in obese patients but needs more research to confirm safety and effectiveness.
April 2022 in “JAAD case reports” Alitretinoin helped clear up a skin condition called generalized granuloma annulare in an elderly man.
June 2026 in “Quality in Sport” Treating hirsutism and acne in women with PCOS needs a personalized approach using oral contraceptives, antiandrogens, and sometimes metformin.
March 2026 in “Anti-Aging Eastern Europe” PCOS treatment should be personalized based on individual symptoms and health goals.
October 2025 in “Brazilian Journal of Hair Health” Hair loss from weight-loss treatments is usually temporary and reversible.
GLP-1 receptor agonists can cause skin and hair issues due to rapid weight loss, but these can be managed with proper care and treatments.
May 2025 in “International Journal of Women’s Dermatology” 5-alpha reductase inhibitors and spironolactone don't increase gynecological tumor risk, glucagon-like-peptide-1 receptor agonists may increase alopecia risk, sanitary pads can cause dermatitis, early hidradenitis suppurativa intervention is crucial for Hispanic patients, community education boosts skin cancer awareness, metformin may improve skin cancer survival, LNG-IUDs can increase acne risk, machine learning accurately detects basal cell carcinoma, JAK-inhibitors may raise miscarriage risk, inclusive skincare ads affect those with darker skin, and CCCA in Black women might involve autoimmunity.